Latest Rare Diseases News

Page 7 of 7

Percheron Halts Avicursen Trial, Raises $14.85M to Pivot Pipeline Strategy

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.

Ada Torres

31 Jan 2025

Browse the archive

Full archive

Oct 2026 Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026